Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06888661 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients With Spinal Muscular Atrophy

StatusEnrolling by Invitation
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 21, 2025 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this trial is to evaluate safety and efficacy of intrathecal delivery of EXG001-307 as a treatment of spinal muscular atrophy .
Trial Details
NCT Number NCT06888661
Lead Sponsor Guangzhou Jiayin Biotech Ltd
Conditions Spinal Muscular Atrophy (SMA)
Enrollment 4 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov